TGN-020 ameliorates motor dysfunction post-spinal cord injury via enhancing astrocyte autophagy and mitigating inflammation by activating AQP4/PPAR-γ/mTOR pathway

Exp Neurol. 2024 Dec:382:114975. doi: 10.1016/j.expneurol.2024.114975. Epub 2024 Sep 24.

Abstract

Spinal Cord Injury (SCI) is a severe condition that often leads to substantial neurological impairments. This study aimed to explore the role of Aquaporin-4 (AQP4) in regulating astrocyte autophagy and neuroinflammation post-SCI, as well as to evaluate the therapeutic potential of AQP4 inhibition using the specific inhibitor TGN-020. Using Western blot, CCK8 assays, immunofluorescence staining, histopathological assessments, and behavioral analyses, we investigated the effects of TGN-020 on SCI-induced alterations in autophagy, neuroinflammation, astrocyte proliferation, neuronal damage, and motor function recovery in both rat and astrocyte models. Our findings indicate that TGN-020 significantly enhances astrocyte autophagy, reduces neuroinflammation, thereby leading to mitigated astrocyte activation by suppressing AQP4 expression. These beneficial effects are associated with the activation of the peroxisome proliferator-activated receptor-γ/mammalian target of rapamycin (PPAR-γ/mTOR) signaling pathway. Notably, the introduction of the PPAR-γ specific inhibitor GW9662 abrogated the positive regulatory effects of TGN-020 on SCI-induced autophagy and neuroinflammation. Collectively, our in vivo and in vitro experiments demonstrate that TGN-020, by down-regulating AQP4, activates the PPAR-γ/mTOR pathway, ameliorates astrocyte autophagy, diminishes neuroinflammation, and ultimately enhances motor function recovery.

Keywords: Aquaporin-4; Autophagy; Inflammation; PPAR-γ/mTOR; Spinal cord injury.

MeSH terms

  • Animals
  • Aquaporin 4* / antagonists & inhibitors
  • Aquaporin 4* / metabolism
  • Astrocytes* / drug effects
  • Astrocytes* / metabolism
  • Autophagy* / drug effects
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Male
  • Neuroinflammatory Diseases / drug therapy
  • Neuroinflammatory Diseases / metabolism
  • Niacinamide / analogs & derivatives
  • PPAR gamma* / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction* / drug effects
  • Spinal Cord Injuries* / drug therapy
  • Spinal Cord Injuries* / metabolism
  • Spinal Cord Injuries* / pathology
  • TOR Serine-Threonine Kinases* / antagonists & inhibitors
  • TOR Serine-Threonine Kinases* / metabolism
  • Thiadiazoles / pharmacology
  • Thiadiazoles / therapeutic use

Substances

  • (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
  • 2-(nicotinamide)-1,3,4-thiadiazole
  • Aqp4 protein, rat
  • Aquaporin 4
  • mTOR protein, rat
  • Niacinamide
  • PPAR gamma
  • Thiadiazoles
  • TOR Serine-Threonine Kinases